Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP
| Autor: | Junichi Taniguchi, Kazuhiro Kitajima, Syuji Ueda, Hiroyuki Kawamoto, Hiroya Tamaki, Masaya Okada, Yoshihiro Fujimori, Akihiro Sawada, Koichiro Yamakado, Tazuko Tokugawa, Satoshi Yoshihara, Kyoko Yoshihara |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Vincristine PET-CT 03 medical and health sciences 0302 clinical medicine Prednisone Medicine Progression-free survival medicine.diagnostic_test business.industry non-Hodgkin lymphoma medicine.disease Lymphoma 030104 developmental biology Oncology Positron emission tomography 030220 oncology & carcinogenesis Rituximab Radiology business Diffuse large B-cell lymphoma progression-free survival Research Paper medicine.drug |
| Zdroj: | Oncotarget Scopus-Elsevier |
| ISSN: | 1949-2553 |
| Popis: | Objectives: To examine the prognostic value of interim 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) findings after 2–4 cycles of rituximab, plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) receiving standardized treatment. Results: After a median 3.36 years (range 0.33 to 9.14 years), 24 of the 80 patients had documented relapse. In Interim-PET findings, 2-year PFS was significantly shorter for PET-positive as compared with PET-negative patients (50.0% vs. 86.4%; p = 0.0012). In End-PET findings, 2-year PFS was significantly shorter for PET-positive as compared with PET-negative patients (25.0% vs. 84.7%; p < 0.0001). The positive predictive value (PPV) and negative predictive value (NPV) of Interim-PET for predicting relapse or disease progression were 57.1% and 75.8%, respectively, while those for End-PET were 75.0% and 75.0%, respectively. Methods: Eighty DLBCL patients treated with first-line 6–8 R-CHOP courses regardless of interim imaging findings were enrolled. Each underwent FDG-PET/CT scanning at staging, and again during (Interim-PET) and at the end of (End-PET) therapy. PET positivity or negativity at Interim-PET and End-PET as related to progression-free survival (PFS) was examined using Kaplan–Meier analysis. Conclusion: Mid-treatment FDG-PET/CT findings may be useful for determining disease status in patients with DLBCL undergoing induction R-CHOP chemotherapy, though are not recommended for treatment decisions as part of routine clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|